| Literature DB >> 25965781 |
Geoffrey N Gobert1, Sujeevi K Nawaratna1, Marina Harvie1, Grant A Ramm1, Donald P McManus1.
Abstract
BACKGROUND: We report the use of an ex vivo precision cut liver slice (PCLS) mouse model for studying hepatic schistosomiasis. In this system, liver tissue is unfixed, unfrozen, and alive for maintenance in culture and subsequent molecular analysis. METHODS ANDEntities:
Mesh:
Substances:
Year: 2015 PMID: 25965781 PMCID: PMC4428699 DOI: 10.1371/journal.pntd.0003760
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Fig 1Malondialdehyde (MDA) assay of culture media containing liver slice tissue exposed or not to soluble egg antigen (SEA).
While MDA concentrations in media increased over the 48 hour time course, indicating hepatotoxicity, there was no statistical difference between treatment groups at any time point (p-value>0.05).
Fig 2Correlation of 13,746 genes identified after quality control filtering.
Colouring ranging from r2 = 0.6 for black to r2 = 1 red. Individual samples are grouped by time point and correlation between biological replicates varied between r2 = 0.965–0.985. Correlation between individual time points with pre-cut (whole) tissue resulted in r2 = 0.97 for time point 0 (after cutting and 2 hours rest), 0.88 after 4 hours, 0.73 after 24 hours and 0.57 after 48 hours.
All 48 genes differentially expressed in response to S. japonicum soluble egg antigen (SEA).
| FC SEA / control (hours) | |||||||
|---|---|---|---|---|---|---|---|
| Symbol | 4 | p-Value | 24 | p-Value | 48 | p-Value | Definition |
| il1b | 5.2 | 7.66E-09 | 4.1 | 4.15E-09 | 10.7 | 8.41E-18 | interleukin-1- beta |
| fpr2 | 2.7 | 6.91E-06 | 3.5 | 7.53E-07 | 6.8 | 4.21E-15 | formyl peptide receptor 2 |
| il1a | 2.4 | 1.16E-05 | 3.3 | 2.48E-06 | 4.3 | 2.73E-11 | interleukin-1-alpha |
| saa3 | 1.1 | 3.61E-01 | 1.9 | 4.94E-02 | 3.6 | 2.69E-08 | serum amyloid A 3 |
| cxcl2 | 2.5 | 2.52E-04 | 1.4 | 3.88E-04 | 2.8 | 3.68E-09 | chemokine (C-X-C motif) ligand 2 |
| irak3 | 1.2 | 8.93E-03 | 1.8 | 9.76E-05 | 2.5 | 3.64E-08 | interleukin-1 receptor-associated kinase 3 |
| ccl3 | 2.8 | 5.90E-06 | 2.3 | 3.50E-09 | 2.4 | 1.46E-08 | chemokine (C-C motif) ligand 3 |
| s100a8 | 1.0 | 2.54E-01 | 2.5 | 6.33E-06 | 2.3 | 4.83E-09 | S100 calcium binding protein A8 |
| ms4a7 | 1.1 | 6.46E-02 | 1.3 | 2.38E-03 | 2.0 | 9.47E-08 | membrane-spanning 4-domains, subfamily A, member 7 |
| fpr1 | 1.0 | 3.89E-01 | 1.5 | 1.98E-04 | 1.8 | 3.85E-06 | formyl peptide receptor 1 |
| tlr2 | 1.3 | 1.41E-02 | 1.3 | 9.44E-04 | 1.8 | 4.91E-06 | toll-like receptor 2 |
| ccl4 | 2.0 | 2.27E-02 | 1.5 | 3.98E-03 | 1.6 | 5.95E-04 | chemokine (C-C motif) ligand 4 |
| h2-m2 | 1.0 | 7.29E-01 | 1.7 | 3.32E-05 | 1.6 | 3.03E-05 | histocompatibility 2, M region locus 2 |
| cd207 | 1.7 | 8.02E-06 | 1.3 | 1.99E-03 | 1.5 | 5.36E-03 | CD207 antigen |
| fyb | 1.0 | 7.36E-01 | 1.5 | 5.59E-05 | 1.5 | 3.64E-04 | FYN binding protein |
| clecsf9 | 1.5 | 4.26E-05 | 2.0 | 2.86E-06 | 1.4 | 1.16E-03 | C-type lectin domain superfamily member 9 |
| e330036i19rik | 1.2 | 3.52E-02 | 1.2 | 3.40E-03 | 1.4 | 5.26E-04 | RIKEN cDNA E330036I19 gene |
| pla2g15 | 1.0 | 5.21E-01 | 1.4 | 4.24E-05 | 1.4 | 3.27E-04 | phospholipase A2, group XV |
| tiam1 | 1.0 | 3.87E-01 | 1.1 | 1.98E-01 | 1.4 | 2.09E-04 | T-cell lymphoma invasion and metastasis 1 |
| tnip1 | 1.6 | 5.77E-03 | 1.3 | 6.00E-04 | 1.4 | 2.39E-04 | TNFAIP3 interacting protein 1 |
| traf1 | 1.2 | 1.08E-02 | 1.6 | 2.77E-06 | 1.4 | 8.16E-04 | Tnf receptor-associated factor 1 |
| cd40 | 1.6 | 8.85E-01 | 1.5 | 2.35E-01 | 1.3 | 3.05E-01 | CD40 antigen |
| ebi3 | 1.0 | 3.37E-01 | 1.2 | 2.42E-03 | 1.3 | 4.24E-03 | Epstein-Barr virus induced gene 3 |
| gpr84 | 1.1 | 8.53E-02 | 1.5 | 1.27E-04 | 1.3 | 2.47E-02 | G protein-coupled receptor 84 |
| mmp13 | 5.0 | 1.03E-06 | 1.9 | 6.39E-02 | 1.3 | 1.64E-01 | matrix metallopeptidase 13 |
| osm | 1.0 | 9.90E-01 | 1.1 | 4.74E-02 | 1.3 | 4.28E-03 | oncostatin M |
| pilrb1 | 1.0 | 2.54E-01 | 1.3 | 2.22E-03 | 1.3 | 5.05E-03 | paired immunoglobin-like type 2 receptor beta 1 |
| ppnr | 1.1 | 1.22E-01 | 1.2 | 3.50E-02 | 1.3 | 3.97E-03 | per-pentamer repeat gene |
| spic | 1.1 | 4.88E-01 | 1.3 | 7.35E-03 | 1.3 | 9.31E-02 | Spi-C transcription factor |
| tcf7l2 | 1.0 | 2.67E-01 | 1.1 | 1.49E-02 | 1.3 | 1.29E-03 | transcription factor 7-like 2, T-cell specific, HMG-box |
| tnfaip2 | 1.4 | 8.97E-03 | 1.0 | 9.09E-01 | 1.3 | 4.32E-02 | tumor necrosis factor, alpha-induced protein 2 |
| 2610027c15rik | 1.2 | 1.76E-02 | 1.1 | 2.12E-01 | 1.2 | 2.07E-02 | RIKEN cDNA 2610027C15 gene |
| adora2b | 1.2 | 4.70E-03 | 1.3 | 7.90E-04 | 1.2 | 5.89E-02 | adenosine A2b receptor |
| arg2 | 1.0 | 2.15E-01 | 1.2 | 4.86E-02 | 1.2 | 6.08E-02 | arginase type II |
| cd33 | 1.0 | 7.87E-01 | 1.4 | 7.39E-06 | 1.2 | 1.95E-02 | CD33 antigen |
| flrt3 | 1.0 | 3.51E-01 | 1.4 | 8.03E-03 | 1.2 | 4.11E-02 | fibronectin leucine rich transmembrane protein 3 |
| loc100048721 | 1.1 | 1.70E-01 | 1.3 | 5.34E-03 | 1.2 | 4.41E-02 | similar to fibronectin leucine rich transmembrane protein 3 |
| slco3a1 | 1.2 | 4.29E-01 | 1.2 | 2.00E-01 | 1.2 | 8.91E-01 | solute carrier organic anion transporter family, member 3a1 |
| zdhhc14 | 1.1 | 1.28E-01 | 1.1 | 8.25E-02 | 1.2 | 3.52E-02 | zinc finger, DHHC domain containing 14 |
| clec4e | 1.3 | 3.23E-03 | 1.4 | 6.68E-04 | 1.1 | 1.05E-01 | C-type lectin domain family 4, member e |
| micall2 | 1.1 | 2.59E-01 | 1.3 | 2.05E-03 | 1.1 | 6.47E-02 | MICAL-like 2 |
| plagl2 | 1.1 | 1.36E-01 | 1.2 | 5.22E-03 | 1.1 | 1.67E-01 | pleiomorphic adenoma gene-like 2 |
| slc31a2 | 1.0 | 6.87E-01 | 1.3 | 7.77E-04 | 1.1 | 7.59E-02 | Solute Carrier Family 31 (Copper Transporter), Member 21 |
| tug1 | 1.0 | 8.76E-01 | 1.1 | 8.88E-01 | 1.1 | 7.83E-01 | taurine upregulated gene 1 |
| csf1 | 1.4 | 8.84E-03 | 1.5 | 7.07E-04 | 1.0 | 5.99E-01 | colony stimulating factor 1 |
| tmem132e | 1.2 | 1.94E-02 | 1.2 | 4.67E-03 | 1.0 | 8.93E-01 | transmembrane protein 132E |
| pld4 | 1.1 | 4.52E-02 | 1.3 | 6.23E-04 | -2.0 | 5.35E-08 | phospholipase D family, member 4 |
| lpl | 1.5 | 3.20E-03 | -2.5 | 2.93E-06 | -5.2 | 1.82E-12 | lipoprotein lipase |
Gene expression (fold change; FC), with associated p-values, relative to control tissues in the ex vivo native mouse liver model over 48 hours after the addition of SEA determined using t-tests with multiple testing correction p≤0.05 (Benjamin-Hochberg).
Novel differentially expressed genes in response to S. japonicum soluble egg antigen (SEA).
| FC SEA / control (hours) | |||||||
|---|---|---|---|---|---|---|---|
| Symbol | 4 | p-Value | 24 | p-Value | 48 | p-Value | Definition |
| angpt2 | -3.1 | 1.20E-05 | 1 | 9.96E-01 | 1.1 | 1.00E+00 | angiopoietin 2 |
| aqp1 | 1 | 4.78E-01 | -3 | 1.40E-04 | -2.3 | 2.80E-03 | aquaporin 1 |
| ccl2 | 1.8 | 9.19E-03 | 1.7 | 1.47E-02 | 1.3 | 1.00E+00 | chemokine (C-C motif) ligand 2 |
| ccl7 | 1.1 | 6.38E-01 | 1.8 | 3.38E-02 | 1.7 | 1.00E+00 | chemokine (C-C motif) ligand 7 |
| ccrl2 | 1.4 | 1.44E-02 | 1.5 | 1.14E-02 | 1.2 | 1.00E+00 | chemokine (C-C motif) receptor-like 2 |
| cd14 | 1.3 | 1.07E-01 | 1.2 | 1.70E-01 | 1.9 | 6.04E-04 | CD14 antigen |
| col1a1 | -1.1 | 2.65E-01 | -1.1 | 2.61E-01 | 1.4 | 6.64E-03 | procollagen, type I, alpha 1 |
| col5a1 | 1.1 | 3.80E-01 | 1 | 8.40E-01 | 1.7 | 3.41E-01 | procollagen, type V, alpha 1 |
| cxcl1 | 1.1 | 2.60E-01 | 1 | 7.51E-01 | 2.2 | 2.30E-05 | chemokine (C-X-C motif) ligand 1 |
| cxcl16 | 1.6 | 2.10E-03 | 1.5 | 3.18E-04 | 1.3 | 9.30E-01 | chemokine (C-X-C motif) ligand 16 |
| fstl1 | 1 | 8.81E-01 | -1.1 | 2.61E-01 | 1.7 | 1.26E-01 | follistatin-like 1 |
| ifit3 | -1.2 | 4.36E-01 | 2.3 | 3.09E-02 | 1 | 1.00E+00 | interferon-induced protein with tetratricopeptide repeats 3. |
| iigp2 | -1.5 | 1.91E-03 | 1.8 | 1.74E-06 | 1.1 | 1.00E+00 | interferon inducible GTPase 2 |
| il10 | 1.9 | 6.79E-08 | 1.2 | 4.53E-03 | 1.2 | 1.00E+00 | interleukin 10 |
| il11 | -1.3 | 8.55E-02 | -1.2 | 3.57E-01 | 2.4 | 1.06E-04 | interleukin 11 |
| il4i1 | 1.8 | 1.09E-06 | 1.2 | 3.72E-03 | 1.3 | 9.75E-01 | interleukin 4 induced 1 |
| il6 | -1.1 | 3.87E-01 | 1 | 9.50E-01 | 2.3 | 4.17E-03 | interleukin 6 |
| irak3 | 1.3 | 8.93E-03 | 1.8 | 9.76E-05 | 2.6 | 3.34E-05 | interleukin-1 receptor-associated kinase 3 |
| loc100044702 | -1.2 | 2.05E-01 | 1.1 | 5.54E-01 | 2.7 | 4.19E-03 | similar to LPS-induced CXC chemokine. |
| ly6a | -1.4 | 3.47E-03 | 2.1 | 7.11E-04 | 1 | 1.00E+00 | lymphocyte antigen 6 complex, locus A |
| mmp10 | 1 | 7.21E-01 | 1.3 | 1.06E-01 | 1.8 | 1.00E+00 | matrix metallopeptidase 10 |
| mmp3 | 1 | 9.65E-01 | -1.1 | 7.73E-01 | 1.7 | 7.94E-02 | matrix metallopeptidase 3 |
| mmp9 | 1 | 6.94E-01 | 1.4 | 1.14E-01 | 2.1 | 3.44E-03 | matrix metallopeptidase 9 |
| pglyrp1 | -1.1 | 3.78E-01 | 1.2 | 1.24E-02 | 1.7 | 3.12E-03 | Peptidoglycan recognition protein |
| serpinb2 | 1.1 | 1.11E-01 | 1.1 | 5.22E-01 | 2.5 | 4.89E-05 | serine (or cysteine) peptidase inhibitor, clade B, member 2. |
| sod2 | 1 | 9.87E-01 | 1.2 | 3.69E-02 | 1.8 | 9.06E-03 | Superoxide dismutase 2, mitochondrial |
| timp1 | -1.1 | 7.66E-01 | -1.1 | 5.10E-01 | 2.1 | 2.76E-03 | tissue inhibitor of metalloproteinase 1 |
| tnc | 1 | 6.29E-01 | -1.2 | 1.28E-01 | 2.3 | 9.88E-02 | tenascin C |
| tnf | 1.9 | 2.27E-04 | 1.3 | 3.90E-03 | 1.2 | 1.00E+00 | tumor necrosis facto |
| tlr4 | -1.1 | 1.94E-01 | 1 | 9.19E-01 | 1 | 1.00E+00 | toll-like receptor 4 |
Gene expression fold changes (FC) with associated p-value, relative to control tissue in ex vivo native mouse liver model over 48 hours after the addition of SEA. Genes with known roles in immune responses or tissue remodeling are shown.
Top 20 pathways identified by Ingenuity Pathway Analysis.
| Ingenuity Canonical Pathways | P-value | Genes |
|---|---|---|
| Granulocyte Adhesion and Diapedesis | 4.37E-09 | CXCL3, IL1A, CCL4, FPR2, CCL3L1/CCL3L3, MMP13, IL1B, FPR1 |
| Atherosclerosis Signaling | 9.55E-09 | IL1A, CD40, CSF1, LPL, MMP13, IL1B, S100A8 |
| Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis | 2.04E-08 | TLR2, IL1A, CSF1, MMP13, OSM, IL1B, IRAK3, TCF7L2, TRAF1 |
| Communication between Innate and Adaptive Immune Cells | 5.13E-08 | TLR2, IL1A, CCL4, CD40, CCL3L1/CCL3L3, IL1B |
| Hepatic Fibrosis / Hepatic Stellate Cell Activation | 6.46E-07 | CXCL3, IL1A, CD40, CSF1, MMP13, IL1B |
| Altered T Cell and B Cell Signaling in Rheumatoid Arthritis | 1.35E-06 | TLR2, IL1A, CD40, CSF1, IL1B |
| NF-ΰB Signaling | 2.29E-06 | TLR2, IL1A, TNIP1, CD40, IL1B, IRAK3 |
| Agranulocyte Adhesion and Diapedesis | 3.39E-06 | CXCL3, IL1A, CCL4, CCL3L1/CCL3L3, MMP13, IL1B |
| LXR/RXR Activation | 7.41E-06 | IL1A, LPL, IL1B, S100A8, ARG2 |
| Differential Regulation of Cytokine Production in Intestinal Epithelial Cells by IL-17A and IL-17F | 1.82E-05 | IL1A, CCL4, IL1B |
| TREM1 Signaling | 2.40E-05 | TLR2, CXCL3, CD40, IL1B |
| Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis | 1.29E-04 | IL1A, CSF1, MMP13, IL1B, TCF7L2 |
| Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza | 1.32E-04 | IL1A, CCL4, IL1B |
| Role of IL-17F in Allergic Inflammatory Airway Diseases | 1.41E-04 | CCL4, MMP13, IL1B |
| Hepatic Cholestasis | 2.63E-04 | IL1A, SLCO3A1, IL1B, IRAK3 |
| Toll-like Receptor Signaling | 2.69E-04 | TLR2, IRAK3, TRAF1 |
| Role of IL-17A in Psoriasis | 3.80E-04 | CXCL3, S100A8 |
| IL-10 Signaling | 4.79E-04 | IL1A, IL1B, ARG2 |
| Acute Phase Response Signaling | 5.50E-04 | IL1A, Saa3, OSM, IL1B |
| Dendritic Cell Maturation | 6.76E-04 | TLR2, IL1A, CD40, IL1B |
From the 48 differentially expressed genes in response to S. japonicum soluble egg antigen in the ex vivo native mouse liver model over 48 hours.
Fig 3Real time validation of a subset of the 13,746 genes.
Genes were identified both as differentially expressed and unchanged due to the presence of soluble egg antigen (SEA) from Schistosoma japonicum. Relative gene expression was normalised to the house keeping gene HPRT. Time points refer to pre-cut intact tissue (PC) and tissue slices in culture before (0) and after (4, 24 and 48 hours) the addition of soluble egg antigen (SEA). P values = *≤0.05, **≤0.01, ****≤0.0001.
Fig 4Cytokine and chemokine levels were determined in liver section culture supernatants.
Using Legendplex multi-analyte flow assay kits, IL-6, CXCL1, CCL2, CCL3, CCL4, CXCL5 and CCL22 were detected. Levels of significance were calculated using two-way ANOVA with Sidaks multiple comparison test. P values = *≤0.05, **≤0.01, ****≤0.0001, NS = not significant >0.05.